YSB Inc.
YSB Inc. develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. The company offers ClouMinihouse, a primary smart healthcare system that include Future Lou, a series of advanced point-of-care testing and monitoring devices; Cloud consultation SaaS, a digital clinic management system; and ClouWiseDocto… Read more
YSB Inc. (B1S) - Net Assets
Latest net assets as of June 2025: €2.27 Billion EUR
Based on the latest financial reports, YSB Inc. (B1S) has net assets worth €2.27 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.78 Billion) and total liabilities (€4.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.27 Billion |
| % of Total Assets | 33.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
YSB Inc. - Net Assets Trend (2021–2024)
This chart illustrates how YSB Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for YSB Inc. (2021–2024)
The table below shows the annual net assets of YSB Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.27 Billion | +20.45% |
| 2023-12-31 | €1.88 Billion | +143.10% |
| 2022-12-31 | €-4.37 Billion | -50.24% |
| 2021-12-31 | €-2.91 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to YSB Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 464137900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.93 Billion | 427.99% |
| Total Equity | €2.32 Billion | 100.00% |
YSB Inc. Competitors by Market Cap
The table below lists competitors of YSB Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PetroVietnam General Services Corp
VN:PET
|
$145.12 Million |
|
Lict Corporation
PINK:LICT
|
$145.17 Million |
|
ElringKlinger AG
PINK:EGKLF
|
$145.18 Million |
|
Gaming Innovation Group Inc
OL:GIG
|
$145.18 Million |
|
Dong-A St
KO:170900
|
$145.02 Million |
|
DS DANSUK CO., LTD.
KO:017860
|
$145.02 Million |
|
Ramkhamhaeng Hospital Public Company Limited
BK:RAM
|
$144.99 Million |
|
BioInvent International AB (publ)
PINK:BOVNF
|
$144.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in YSB Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,919,762,000 to 2,319,063,000, a change of 399,301,000 (20.8%).
- Net income of 15,081,000 contributed positively to equity growth.
- New share issuances of 19,442,000 increased equity.
- Other factors increased equity by 364,778,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €15.08 Million | +0.65% |
| Share Issuances | €19.44 Million | +0.84% |
| Other Changes | €364.78 Million | +15.73% |
| Total Change | €- | 20.80% |
Book Value vs Market Value Analysis
This analysis compares YSB Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-4.59 | €0.48 | x |
| 2022-12-31 | €-6.88 | €0.48 | x |
| 2023-12-31 | €3.00 | €0.48 | x |
| 2024-12-31 | €3.43 | €0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently YSB Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.08%
- • Asset Turnover: 2.76x
- • Equity Multiplier: 2.80x
- Recent ROE (0.65%) is above the historical average (-41.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -4.97% | 2.94x | 0.00x | €-211.53 Million |
| 2022 | 0.00% | -10.51% | 3.47x | 0.00x | €-1.06 Billion |
| 2023 | -167.03% | -18.89% | 3.26x | 2.71x | €-3.40 Billion |
| 2024 | 0.65% | 0.08% | 2.76x | 2.80x | €-216.83 Million |
Industry Comparison
This section compares YSB Inc.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $58,556,500
- Average return on equity (ROE) among peers: -279.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| YSB Inc. (B1S) | €2.27 Billion | 0.00% | 1.98x | $145.06 Million |
| Redcare Pharmacy NV (RDC) | $18.08 Million | -15.66% | 0.42x | $587.80 Million |
| Rite Aid Corporation (RTA1) | $99.03 Million | -543.74% | 85.12x | $11.16 Million |